All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

EHA2022 abstracts: What's hot in MDS?

To help navigate the exciting content being presented at the EHA2022 Congress, the MDS Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in MDS.

Top abstracts


Clinical characteristics of secondary myeloid neoplasms in patients with inflammatory bowel disease


Real life experience using front-line CPX-351 for therapy-related and AML-MRC: Results from the Spanish PETHEMA registry


The role of SF3B1 mutations in myelodysplastic syndromes


DDX41 mutations define a unique subtype of myeloid neoplasms


Targeting S100A9 in the myelodysplastic inflammatory bone marrow microenvironment by tasquinimod improves the supportive function of mesenchymal stromal cells


Initial results of phase I/II study of azacitidine in combination with quizartinib for patients with myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm with FLT3 or CBL mutation


Results of a phase 1 study of azacitidine combined with venetoclax for treatment-naive and relapsed high-risk myelodysplastic syndrome and chronic myelomonocytic leukemia


Venetoclax with azacitidine in relapse/refractory higher risk myelodysplastic syndrome: updated phase 1 results


Long-term utilization and benefit of luspatercept in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS) from the MEDALIST trial


Combination therapy of eltrombopag and cyclosporine A can improve hematopoiesis in patients with lower risk myelodysplastic syndrome


A phase I/II study of venetoclax in combination with ASTX727 (decitabine/cedazuridine) in treatment‐naïve high‐risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML)


Current cardiovascular disease risk prediction models are not applicable in MDS patients: preliminary results of a prospective observational single-centre cohort study


Real-world erythropoiesis-stimulating agent (ESA) treatment patterns and outcomes among US patients with lower-risk myelodysplastic syndromes (LR-MDS)


Molecular determinants of disease progression after hypomethylating agent therapy in Ras pathway mutant chronic myelomonocytic leukemia at the single-cell level


Integrated genetic diagnostics of patients with early onset of de novo myelodysplastic syndromes


Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1b study results


Prediction of relapse after allogeneic stem cell transplantation using individualized measurable residual disease markers; the prospective Nordic study NMDSG14B


Erythropoietin stimulation agents significantly improves outcome in lower risk MDS


Clinical and molecular markers for predicting response to romiplostim treatment in lower-risk myelodysplastic syndromes

EHA2022 abstracts

To download this document, click below.

Download here

More about...


Subscribe to get the best content related to MDS delivered to your inbox